Punya Shrivastava-Ranjan

Punya Shrivastava-Ranjan

Auto-generated profile, based on publicly available information

Punya Shrivastava-Ranjan

Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
SWStephen R Welch
Stephen R Welch
JSJessica Spengler
Jessica Spengler
JWJonna B. Westover
Jonna B. Westover
KBKevin W. Bailey
Kevin W. Bailey
KDKatherine A. Davies
Katherine A. Davies
MFMichael Flint
Michael Flint
Development of broad-spectrum antiviral therapies is critical for outbreak and pandemic preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic fevers cause high morbidity and mortality in humans and are associated with several recent international outbreaks, but approved therapies for treating most of these pathogens are lacking. Here, we show that 4′-fluorouridine (4′-FlU; EIDD-2749), an orally available ribonucleoside analog, has antiviral activity against multiple hemorrhagic fever viruses in cell culture, including Nipah virus, Crimean-Congo hemorrhagic fever virus, orthohantaviruses, and arenaviruses. We performed preclinical in vivo evaluation of oral 4′-FlU against two arenaviruses, Old World Lassa virus (LASV) and New World Junín virus (JUNV), in guinea pig models of lethal disease. 4′-FlU demonstrated both advantageous pharmacokinetic characteristics and high efficacy in both of these lethal disease guinea pig models. Additional experiments supported protection of the infected animals even when 4′-FlU delivery was reduced to a low dose of 0.5 milligram per kilogram. To demonstrate clinical utility, 4′-FlU treatment was evaluated when initiated late in the course of infection (12 or 9 days after infection for LASV and JUNV, respectively). Delayed treatment resulted in rapid resolution of clinical signs, demonstrating an extended window for therapeutic intervention. These data support the use of 4′-FlU as a potent and efficacious treatment against highly pathogenic arenaviruses of public health concern with a virus inhibition profile suggesting broad-spectrum utility as an orally available antiviral drug against a wide variety of viral pathogens.

23 February 2006 in AfCS-Nature Molecule Pages
Verified
Journal Article
Closed access
RKRichard Kahn
Richard Kahn
PSPunya Shrivastava-Ranjan
Punya Shrivastava-Ranjan

3 May 2023 in Antiviral Research
Verified
Journal Article
Closed access
PSPunya Shrivastava-Ranjan
Punya Shrivastava-Ranjan
SJShilpi Jain
Shilpi Jain
PCPayel Chatterjee
Payel Chatterjee
JMJoel M. Montgomery
Joel M. Montgomery
MFMike Flint
Mike Flint
CSChristina Spiropoulou
Christina Spiropoulou

15 April 2025 in Antiviral Research
Verified
Journal Article
Open access
JKJamie Kelly
Jamie Kelly
VAVirginia Aida-Ficken
Virginia Aida-Ficken
LMLaura K. McMullan
Laura K. McMullan
PCPayel Chatterjee
Payel Chatterjee
PSPunya Shrivastava-Ranjan
Punya Shrivastava-Ranjan
MFMichael Flint
Michael Flint
Cell-based drug repurposing screens have been a common approach to identifying compounds with antiviral properties. For Ebola virus (EBOV), such screens yield unexpectedly high hit rates. We investigated two mechanisms underlying the anti-EBOV activities of repurposed compounds. Phospholipidosis (PLD) is excessive accumulation of cellular lipids that confounds screens for SARS-CoV-2. We performed a meta-analysis of published screens and supplemented these with our own using infectious EBOV at biosafety level-4. A list of nearly 400 hit compounds from seven anti-EBOV screens was compiled. Most (63 %) of these hits were predicted to induce PLD, and their anti-EBOV activities broadly correlated with PLD induction. PLD-inducing compounds did not inhibit infection by several other highly pathogenic viruses, suggesting that PLD was not a confounding factor for screens against Lassa, Crimean-Congo hemorrhagic fever, and Rift Valley fever viruses. Of four cells lines tested, HeLa cells were the least susceptible to PLD induction. In addition to PLD, many of the hit compounds identified disrupt cholesterol homeostasis. Previous research found inhibition of cholesterol synthesis by statins blocked EBOV infection. To understand if compounds inhibiting this mechanism could contribute to high hit rates, we further examined this pathway. We identified multiple additional inhibitors of cholesterol biosynthesis, that also blocked EBOV infection, albeit with varying potency and cytotoxicity across cell lines. EBOV inhibitors that acted through this mechanism were suppressed by the addition of exogenous cholesterol. Our findings help define the effects that contribute to anti-EBOV activities and hence facilitate the selection of lead molecules suitable for subsequent development.

19 May 2025 in Viruses
Verified
Journal Article
Open access
PDF file
PSPunya Shrivastava-Ranjan
Punya Shrivastava-Ranjan
JKJamie Kelly
Jamie Kelly
LMLaura K McMullan
Laura K McMullan
DCDeborah Cannon
Deborah Cannon
LMLaura Morgan
Laura Morgan
CSChristina Spiropoulou
Christina Spiropoulou
Hantaviruses, including the Sin Nombre virus (SNV) and Andes virus (ANDV), are associated with severe global health risks, causing high mortality rates in hantavirus pulmonary syndrome (HPS) patients. Neutralizing antibodies are essential for virus clearance and survival, making neutralization assays critical for understanding immunity and evaluating therapeutic strategies. In this study, we developed a recombinant vesicular stomatitis virus (VSV)-based surrogate system expressing SNV and ANDV glycoproteins (GPCs), enabling neutralization studies under biosafety level 2 conditions. The neutralization titers obtained with the VSV-based system closely matched the findings from authentic hantavirus assays performed under biosafety level 3 conditions, confirming its potential as a useful tool for determining immune responses and advancing hantavirus research.

24 April 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
HPHelen M. Parrington
Helen M. Parrington
NKNurgun Kose
Nurgun Kose
EAErica Armstrong
Erica Armstrong
LHLaura Handal
Laura Handal
SDSummer Diaz
Summer Diaz
JCJames E. Crowe
James E. Crowe
Sosuga virus (SOSV) is a recently discovered paramyxovirus with a single known human case of disease. There has been little laboratory research on SOSV pathogenesis or immunity, and no approved therapeutics or vaccines are available. Here, we report the discovery of human mAbs from the circulating memory B cells of the only known human case and survivor of SOSV infection. We isolated 6 mAbs recognizing the functional attachment protein hemagglutinin-neuraminidase (HN) and 18 mAbs against the fusion (F) protein. The anti-HN mAbs all targeted the globular head of the HN protein and could be organized into 4 competition-binding groups that exhibited epitope diversity. The anti-F mAbs can be divided into pre- or postfusion conformation-specific categories and further into 8 competition-binding groups. The only Ab in the panel that did not display neutralization activity was the single postfusion-specific anti-F mAb. Most of the anti-HN mAbs were more potently neutralizing than the anti-F mAbs, with mAbs in 1 of the HN competition-binding groups possessing ultrapotent (<1 ng/mL) half-maximal inhibitory virus neutralization values. These findings provide insight into the molecular basis for human Ab recognition of paramyxovirus surface proteins and the mechanisms of SOSV neutralization.